Lilly Asia Ventures

What is Lilly Asia Ventures?

Lilly Asia Ventures (LAV) is a prominent venture capital firm founded in 2008, specializing in the life sciences and healthcare sectors, with a strategic emphasis on the Asian market, particularly China. The firm is renowned for providing smart capital and aspires to be the trusted partner for exceptional entrepreneurs aiming to create outstanding companies.

LAV focuses on a number of sub-sectors within the life sciences field, including biopharmaceuticals, human therapeutics, medical devices, and diagnostics. They are dedicated to the development of breakthrough products that possess the potential to effectively treat diseases and enhance human health.

With their domain expertise, global resources, and commitment to long-term investment, they position themselves as long-term thinkers who prioritize people, innovative products, and high-quality science.

Lilly Asia Ventures prides itself on its effective course in combating diseases and saving lives. Their minimum investment threshold is 18 million USD and they can invest up to 400 million USD. LAV operates from three strategic locations: their headquarters in Shanghai, an office in Hong Kong, and another in Palo Alto, California.

This geographical spread allows them to engage a broad network and contribute to their portfolio companies' successes on a global scale. Their vision and philosophy reflect a commitment to fostering lasting relationships with their portfolio companies and supporting them through the various stages of growth.

LAV is known for leveraging their international perspective to advance healthcare innovation and investment in areas that are in critical need of development and support.